Neural antibodies (also called neuronal or neuroglial autoantibodies) are immune proteins targeting components of the nervous system—neurons, glia, synaptic proteins, or intracellular antigens. They serve as key biomarkers for autoimmune neurological disorders, such as autoimmune encephalitis, paraneoplastic syndromes, neuromyelitis optica spectrum disorder (NMOSD), and certain neuropathies or movement disorders.01

“Neurogenimicsvand” appears to be a typo for “Neurogenomics and”. Neurogenomics studies the genome’s role in nervous system function and disease (e.g., via GWAS, gene expression in neural tissues). There is no major established direct field called “neurogenomics and neural antibodies,” but overlaps exist through genetic predispositions (e.g., HLA alleles) that influence autoantibody development, plus emerging “antibody-omics” or autoantibody repertoire studies in neurological conditions.42

Key Concepts in Neural Antibodies

Neural antibodies fall into two main groups based on target location, which affects pathogenicity, cancer association, and treatment response:

• Extracellular (cell-surface/synaptic) antibodies: Often directly pathogenic (e.g., by blocking receptors, causing internalization, or activating complement). Better immunotherapy response; variable cancer risk.1
  • Examples: NMDAR (anti-N-methyl-D-aspartate receptor) — common in young women, linked to ovarian teratoma, causes psychiatric symptoms, seizures, dyskinesias.
  • LGI1 — older males, faciobrachial dystonic seizures, limbic encephalitis.
  • Others: CASPR2, AMPAR, GABA-A/B receptors, AQP4 (NMOSD), MOG (MOGAD), IgLON5, etc.
• Intracellular (onconeural/paraneoplastic) antibodies: Often markers of T-cell mediated damage; stronger cancer association (e.g., small-cell lung cancer, breast, testicular). Poorer response to immunotherapy alone.7
  • Examples: Hu (ANNA-1), Yo (PCA-1), Ri, CRMP-5, Ma2, amphiphysin.

Many syndromes involve phenotype-specific panels (e.g., encephalitis, ataxia, neuropathy). Testing ideally uses both serum and CSF, with two methods (e.g., tissue immunofluorescence screening + confirmatory cell-based assay, blot, or IP-MS) for reliability.0

Clinical Utility

• Diagnosis: Rapid identification turns “idiopathic” or presumed degenerative/psychiatric cases into treatable autoimmune ones. Many are reversible with early immunotherapy (steroids, IVIG, rituximab, etc.).12
• Prognosis & Cancer Screening: Guides tumor search (high-, intermediate-, or low-risk based on antibody).
• Monitoring: Titers (especially GAD65) can have limited utility; clinical correlation is essential. False positives/negatives occur, so interpret in clinical context.11

Common testing is available through specialized labs (e.g., Mayo Clinic, Cleveland Clinic panels for autoimmune encephalopathy).

Links to Neurogenomics/Genetics

• Some autoantibodies show genetic associations (e.g., specific HLA-DR/DQ alleles for NMDAR or LGI1).1
• GWAS and studies link immune-checkpoint genes, APOE4, and prior brain injury (e.g., trauma) to anti-brain autoantibody risk.42
• Broader “brain antibody-omics” explores how autoantibody profiles (even in healthy people) might influence neurodegeneration, aging, or post-stroke dementia.2
• Neurogenomics tools (e.g., sequencing, protein arrays, PhIP-Seq) accelerate discovery of new antibodies and understand tolerance breakdown.6

Autoimmune neurology is a fast-moving field with ongoing antibody discoveries. If this relates to symptoms, testing, or a specific condition, provide more details for tailored info. Consult a neurologist (ideally neuroimmunologist) for clinical advice—testing should be phenotype-driven, not shotgun.